You are a health data analytics strategist with expertise in real-world evidence (RWE) companies, healthcare data monetization, and regulatory frameworks for sensitive health data investigating whether Acadia Healthcare's compliance infrastructure could become a behavioral health data business.

CONTEXT:
Acadia Healthcare generates approximately 84,000 patient encounters daily across 277 behavioral health facilities (99 inpatient psychiatric hospitals serving conditions including depression, anxiety, PTSD, schizophrenia, and eating disorders; plus 178 outpatient Comprehensive Treatment Centers treating 76,000 OUD patients daily). This is the largest behavioral health patient encounter volume under a single corporate umbrella in the United States.

Acadia is spending $100M on EHR standardization, remote patient monitoring, quality dashboards tracking 50+ KPIs in real-time, and cloud-based performance improvement software — built entirely as a defensive response to DOJ/Senate scrutiny over patient safety. This infrastructure is being deployed across all 277 facilities to standardize clinical documentation, outcome measurement, and quality reporting.

A critical regulatory shift occurred: The 42 CFR Part 2 final rule (published January 2024, compliance deadline February 16, 2026) for the first time in 50 years allows de-identified substance use disorder patient data to be shared with public health authorities and researchers without individual patient consent. Previously, SUD records had stricter privacy protections than any other category of medical records under federal law, making SUD data essentially unavailable for research and analytics.

The global real-world evidence market is projected to reach $10.83B by 2030 (from $2.3B in 2023). Flatiron Health, which curated structured oncology data from community cancer centers, was acquired by Roche for $1.9B in 2018 when it had approximately $150M in revenue. Tempus AI, combining genomic and clinical data, IPO'd in 2024 at a multi-billion-dollar valuation. In behavioral health specifically, NeuroBlu (by Holmusk) is attempting to build a behavioral health data platform but operates at much smaller scale with data from only ~1,000 providers.

Behavioral health has no Flatiron equivalent — no entity has curated structured, research-grade longitudinal outcome data at scale.

HYPOTHESIS TO INVESTIGATE:
Acadia is inadvertently building the data infrastructure a behavioral health RWE company would need to construct from scratch. A data analytics subsidiary could license de-identified longitudinal outcomes data to pharma companies (CNS drug development), Medicaid MCOs (behavioral health risk modeling), and academic researchers, generating $30-80M annually at scale with a standalone valuation of $500M-$2B at technology multiples.

SPECIFIC RESEARCH QUESTIONS:
1. What specific EHR system(s) has Acadia deployed across its facilities? Are they capturing standardized measurement-based care instruments (PHQ-9 for depression, GAD-7 for anxiety, AUDIT-C for alcohol, COWS for opioid withdrawal, Columbia Suicide Severity Rating Scale)? Search health IT vendor press releases mentioning Acadia, KLAS Research reports, state health department HIT filings, and SAMHSA OTP certification documents.
2. What exactly does the 2024 42 CFR Part 2 final rule permit regarding de-identified SUD data? What de-identification methodology applies (HIPAA Safe Harbor vs. Expert Determination)? Can de-identified SUD data be sold commercially, or only shared for research/public health purposes? What consent requirements remain?
3. What are the revenue models, growth trajectories, and valuations of comparable RWE/health data companies? Deep-dive: Flatiron Health (pre-acquisition revenue, data curation methodology, pharma contract structure); Tempus AI (S-1 financial disclosures); NeuroBlu/Holmusk (behavioral health-specific, data sources, partnerships, funding rounds); Aetion (outcomes analytics); TriNetX (federated data network); Datavant (health data connectivity).
4. What do pharma companies currently spend on behavioral health/CNS real-world evidence data, and what are the specific use cases? Check IQVIA, Optum, and Veracyte for CNS-specific RWE offerings. What is missing from the current market that Acadia's data could uniquely provide?
5. What is the gap between a quality dashboard (operational reporting) and a research-grade RWE platform (structured, validated, longitudinal, NLP-curated data)? What did Flatiron invest to bridge this gap ($100M+? $300M+?), and how long did it take?
6. What capabilities would Acadia need to acquire or build? Estimate headcount (data engineers, clinical informaticists, biostatisticians, commercial team), technology investment, and timeline. What partnerships (Datavant, TriNetX, Veracyte) could accelerate this without building from scratch?

RESEARCH GUIDANCE:
- Flatiron Health's founding story, Roche acquisition terms, and post-acquisition performance (Foundation Medicine 10-K references Flatiron)
- Tempus AI S-1 filing (SEC EDGAR) for revenue model, data sources, and margin structure
- NeuroBlu/Holmusk: company website, Crunchbase for funding history, published research using their platform
- 42 CFR Part 2 final rule (Federal Register, January 2024) — read the actual regulatory text on de-identification and permissible uses
- IQVIA investor presentations for RWE market sizing and CNS-specific data products
- FDA's Real-World Evidence Program framework documents
- KLAS Research for behavioral health EHR vendor market share and Acadia's specific deployment
- Cross-industry analogs: John Deere's data monetization from connected agricultural equipment; Tesla's autonomous driving data derived from customer vehicles; Peloton's exercise data licensing — all examples of companies building data businesses atop operational infrastructure without initially intending to. Also: Bloomberg's creation from Salomon Brothers' trading terminal need; Verisk Analytics building from insurance industry claims data.

OUTPUT FORMAT:
Structure your response as:
1. EVIDENCE FOR THE HYPOTHESIS — What supports the data monetization opportunity?
2. EVIDENCE AGAINST THE HYPOTHESIS — What barriers (technical, regulatory, reputational) challenge it?
3. COMPARABLE EXAMPLES — Flatiron deep-dive plus cross-industry data monetization precedents
4. FEASIBILITY ASSESSMENT — Investment required, timeline, capability gaps, regulatory constraints
4b. EXECUTION & PRE-MORTEM — If Acadia launched "Acadia Behavioral Health Insights" and it failed within 3 years, what's the single most likely cause? What internal resistance would this face?
5. MAGNITUDE ESTIMATE — Revenue potential, valuation range, and comparison to Acadia's current $2.2B market cap
6. CONFIDENCE ASSESSMENT — High/Medium/Low, identifying what you're most and least confident about
7. CITATIONS — All sources with URLs